News

Signify Health, a U.S. healthcare platform, has added spirometry testing for chronic obstructive lung disease (COPD) to its in-home diagnostic and preventive services. The company began offering spirometry testing in select locations earlier this year, with at-home evaluations available to Medicare Advantage and Medicaid plan members. “In-home…

Ensifentrine, an inhaled treatment being developed by Verona Pharma, lowered the rate of exacerbations, or episodes of sudden disease worsening, across all subgroups of patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) in the Phase 3 ENHANCE-2 trial. “We are very encouraged by the meaningful and consistent reductions…

AeroRx Therapeutics is teaming up with HCmed Innovations to develop a new therapeutic combination of different classes of bronchodilators — medications that help open up the airways, making breathing easier — for the treatment of people with chronic obstructive pulmonary disease (COPD). The new combo would be delivered using…

The University of Massachusetts Chan Medical School and Wellinks have launched “Healthy at Home,” a program to investigate whether virtual care can prevent recurrent illness and reduce health-related costs for people with chronic obstructive pulmonary disease (COPD). The six-month program will test the feasibility of virtual preventive care…

Despite treatment, a large number of people with chronic obstructive pulmonary disease (COPD) in the U.S. continue to experience a high symptom burden and frequent exacerbations, or episodes of sudden disease worsening, a study reported. Findings highlight the need to better understand the real-world effectiveness of COPD management strategies…

Nighttime breathing symptoms related to chronic obstructive pulmonary disease (COPD) significantly impaired daily activities and health-related quality of life, a survey of patients and physicians revealed. Most of the surveyed patients (74%) reported having nocturnal symptoms, while physicians reported that they prescribed treatments based on 24-hour symptom relief for…

Nuance Pharma has been given the go-ahead to launch clinical trials in China to evaluate the investigational therapy ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The company asked permission, in the form of an investigational new drug (IND) application, to conduct both Phase 1…

Most people with chronic obstructive pulmonary disease (COPD) who participated in a U.S. pilot program of NuvoAir’s virtual monitoring service reported a decrease in hospitalizations and a better quality of life, the company announced. NuvoAir’s COPD solution uses proprietary home monitoring devices, including a spirometer and an…

Ensifentrine, Verona Pharma’s experimental inhalation therapy, safely and effectively improves lung function and reduces the rate and risk of exacerbations, or episodes of disease worsening, in people with moderate to severe chronic obstructive pulmonary disease (COPD). That is according to top-line, six-month data from the Phase 3 ENHANCE-2…

An experimental anti-inflammatory medication called DMX-700, being developed by Dimerix for chronic obstructive pulmonary disease (COPD), was found to substantially reduce lung injury in a mouse model of the disease. “DMX-700 has demonstrated some very encouraging pre-clinical data,” Nina Webster, PhD, CEO and managing director of Dimerix,…